AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Instagram Outage Disrupts Thousands of U.S. Users 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
 Annual Meeting - EconoTimes)
SEOUL, South Korea, May 15, 2017 -- ToolGen, Inc. (KONEX, 199800), a biotechnology company specializing in genome editing, presented results from a study highlighting the use of CRISPR/Cas9 nucleases for specific and efficient genome editing in human primary T-cells, without causing severe cell damage and growth retardation in a poster presentation at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting being held in Washington, DC from May 10-13, 2017.
The poster presentation entitled “Genome editing of human T cells to generate CAR-T cells with enhanced antitumor function” aimed to study the proposed idea that T-cell anergy serves to induce dysfunction in a wide variety of tumor microenvironments. Using CRISPR/Cas9-mediated gene editing, the researchers were able to successfully knock out DGKα, a tolerance-associated gene at an 80% efficiency rate, which allowed T-cells to reverse hypofunction induced by anergy. Based on this result, the researchers combined the lentiviral delivery of CAR and the electroporation of RNP to generate a CRISPR gene-edited CAR-T cell. These edited CAR-T cells demonstrated lower sensitivity to immunosuppressive conditions and were hyper-responsive against tumor cells.
“We are honored to be recognized by ASGCT for our work using CRISPR/Cas9-mediated gene editing,” commented Seokjoong Kim, Research Director at Toolgen. “The data presented in the poster presentation demonstrates preliminary success in utilizing CRISPR/Cas9 nucleases for specific and efficient gene editing in human primary T-cells. The findings suggest that CAR and TCR T cells with a disrupted anergy-related gene may be potent effector cells against various cancers. We believe that these results continue to validate our approach to gene editing and provide support for further research to move our pipeline of opportunities into the clinic.”
The authors of the presentation were Yoon-Young Kim, In Young Jung, Ho Sung Yu1, Seokjoong Kim, R&D Center, Toolgen, Inc., Seoul, South Korea
About ToolGen, Inc.
ToolGen, Inc. is a biotechnology company focused on the development and application of genome editing technologies. It creates, and holds intellectual property rights for essential tools and technologies for editing the genetic information in microbial, plant, animal, and human cells. ToolGen’s mission is to translate the potential of our innovative platform technology into transformative products for biomedicine and agriculture. For more information, please visit www.toolgen.com.
Investor Relations Contact The Ruth Group Tram Bui / Alexander Lobo Phone: 646-536-7035 / 7037 [email protected] [email protected]
